Aims: To investigate health-related quality of life (HRQoL) in short children born small for gestational age (SGA) during growth hormone (GH) treatment and additional postponement of puberty by gonadotropin-releasing hormone analogue (GnRHa). Methods: HRQoL was studied longitudinally during 2 years of treatment in 97 short SGA children (mean age 11.6 years at start). The children were divided into three groups: prepubertal GH-treated (prep-GH) children, pubertal GH-treated (pub-GH) children, and pubertal GH-treated children with additional GnRHa treatment (pub-GH/GnRHa). HRQoL was measured by generic (TACQOL) and short stature-specific (TACQOL-S) questionnaires. Results: The TACQOL-S showed that prep-GH children experienced significant HRQoL improvement on the subscales ‘contact with adults’, ‘body image’ and ‘vitality’, and pub-GH/GnRHa children on the subscales ‘contact with adults’, ‘contact with peers’ and ‘physical abilities’. Parents of prep-GH and pub-GH/GnRHa children reported significant HRQoL improvement on most TACQOL-S scales, whereas HRQoL improvement in pub-GH children reached significance for ‘future prospects’ only. The HRQoL gain was similar in the three groups, also after correction for confounders. The generic questionnaire TACQOL did not reveal any changes. Conclusions: HRQoL improved in prepubertal and pubertal short SGA children during GH treatment. Additional GnRHa treatment had no adverse effect on the HRQoL gain. Disorder-specific questionnaires were particularly appropriate to evaluate HRQoL in children treated for short stature.